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Abstract
Background: Shared decision making contributes to high quality healthcare by promoting a patient-centered
approach. Patient involvement in selecting the components of a diabetes medication program that best match the
patient’s values and preferences may also enhance medication adherence and improve outcomes. Decision aids are
tools designed to involve patients in shared decision making, but their adoption in practice has been limited. In
this study, we propose to obtain a preliminary estimate of the impact of patient decision aids vs. usual care on
measures of patient involvement in decision making, diabetes care processes, medication adherence, glycemic and
cardiovascular risk factor control, and resource utilization. In addition, we propose to identify, describe, and explain
factors that promote or inhibit the routine embedding of decision aids in practice.
Methods/Design: We will be conducting a mixed-methods study comprised of a cluster-randomized, practical,
multicentered trial enrolling clinicians and their patients (n = 240) with type 2 diabetes from rural and suburban
primary care practices (n = 8), with an embedded qualitative study to examine factors that influence the
incorporation of decision aids into routine practice. The intervention will consist of the use of a decision aid (Statin
Choice and Aspirin Choice, or Diabetes Medication Choice) during the clinical encounter. The qualitative study will
include analysis of video recordings of clinical encounters and in-depth, semi-structured interviews with
participating patients, clinicians, and clinic support staff, in both trial arms.
Discussion: Upon completion of this trial, we will have new knowledge about the effectiveness of diabetes
decision aids in these practices. We will also better understand the factors that promote or inhibit the successful
implementation and normalization of medication choice decision aids in the care of chronic patients in primary
care practices.
Trial registration: NCT00388050
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Background
Type 2 diabetes mellitus is a metabolic derangement of
epidemic impact that lowers the quality and duration of
life for millions [1]. The public health impact of this epi-
demic is best understood when considering that diabetes
is associated with an increased risk of premature death
(mostly from cardiovascular causes), cardiovascular dis-
ease, blindness, renal failure, chronic neuropathic pain,
and limb amputations. Successful management of type 2
diabetes requires preventive care and incorporation of
healthy nutritional and activity habits. Pharmacologic
therapy to achieve metabolic control and favorably im-
pact risk factors associated with diabetes-related compli-
cations is almost always necessary. Several medications to
control hyperglycemia, hypertension, and dyslipidemia
have become available in the last decades. Patients who
experience the use of these medicines, often in combin-
ation, and their costs and side effects often report their
burden to exceed the perceived burden of diabetes com-
plications [2,3].
A patient-centered approach to care that promotes pa-
tient involvement in selecting the intensity and compo-
nents of a complex diabetes medication program to
better match patient values and preferences contributes
to high quality care and may enhance medication adher-
ence [4]. Decision aids, tools to help involve patients in
decision making by clearly and accessibly presenting the
available options and their relative advantages and disad-
vantages, may facilitate patient-centered care [5]. In close
collaboration with a multidisciplinary team of patients,
clinicians, and designers, we have developed decision aids
targeting glycemic and cardiovascular risk factor control
through medication therapy (Diabetes Medication
Choice, Statin Choice) [6,7]. These tools have been shown
to improve patient knowledge, involvement in the deci-
sion making process, and satisfaction with healthcare
[6,8]. In addition, ninety percent of the clinicians consid-
ered the decision aids helpful and would use these deci-
sion aids in their practice [8].
Despite their efficacy [5], the adoption of decision aids
in practice has been dismal for reasons that remain
unclear. Furthermore, limited evidence supports our
understanding of how decision aids become routinely
implemented, embedded, and sustained in practice—that
is, how they become normalized. Current approaches to
understanding the implementation of decision aids in
practice have included analyses of the barriers to using de-
cision aids [9], and problems of individual behavioral
change [10] or organizational diffusion. To our know-
ledge, there is no practice-based research focused on how
to normalize these decision aids in the routine of busy
clinical practices and on evaluating the effectiveness of
diabetes decision aids on patient, clinician, and practice
outcomes. Thus, there is urgent need to conduct patient-
centered translational practice-based research in diabetes
care.
To pursue this effort we propose to 1) evaluate, in a
cluster-randomized practical trial enrolling primary care
practices and their patients with type 2 diabetes, the im-
pact of patient decision aids vs. usual care on measures
of patient involvement in decision making, diabetes care
processes, medication adherence, glycemic and cardio-
vascular risk factor control, and resource utilization; and
2) identify, describe, and explain, using a theory-driven
qualitative research approach, factors that promote or
inhibit the routine embedding of decision aids in the
rural and suburban practices participating in the rando-
mized trial.
Methods
Study design
We will be conducting a mixed-methods study com-
prised of a cluster-randomized, practical, multi-centered
trial enrolling primary care practices with a qualitative
study embedded to examine how the practices will be in-
corporating the decision aids into their clinical routines
(Figure 1). The Mayo Clinic and Olmsted Medical Cen-
ter Institutional Review Boards (IRB) have approved the
study procedures described herein.
Setting
We will recruit clinicians and their patients with type 2
diabetes receiving routine diabetes care from participat-
ing primary care practices of Olmsted Medical Center
across rural and suburban communities in Southeastern
Minnesota, USA.
Study participants and eligibility criteria
Clinical practices. Eligible practices are those that have
prioritized chronic disease care as an area for quality im-
provement and have served at least 50 patients with type 2
diabetes in the 12 months prior to the eligibility assessment.
Primary care clinicians. We will recruit clinicians, defined
as professionals with patient healthcare responsibilities (i.e.,
physicians, nurse practitioners, physician assistants), from
participating practices if they are providing care to adults
with type 2 diabetes. Patients. We will consider eligible
adult patients (≥18 years) with type 2 diabetes if they
recognize the participating clinician as their main diabetes
care provider, have no major barriers to provide written
informed consent (e.g., severe hearing impairment, demen-
tia), can communicate in English, and declare being avail-
able for a six-month follow-up. Furthermore, these patients
should need to start, intensify, or modify their antihypergly-
cemic treatment. Additional criteria will be used to identify
eligibility according to designated study arms (Figure 2).
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Participant recruitment
We will send an introductory letter providing an over-
view of the study and inquiring about potential interest
to eligible practices. Study team members will then per-
sonally visit interested clinics to discuss the study in
more detail with clinic leaders. We will identify a lead
clinician (“clinical champion”) to become the contact
person for each practice for the duration of the study
and seek participation of clinicians during this first
meeting when the study is discussed. Potentially eligible
patients will be identified through the diabetes registry,
and we will note their upcoming appointments with par-
ticipating clinicians. A study team member will contact
these patients in advance to seek their participation in
the study. Trained study personnel will obtain written
informed consent to participate in the study from both
clinicians and patients prior to their clinical encounter.
Allocation procedures
Randomization will be by practice. The study will com-
pare the use of the decision aids within the clinical en-
counter versus usual care. We will identify pairs of
practices that are most similar in size (i.e., number of
clinicians seeing adult patients with type 2 diabetes) and
randomize within each pair to use either the 1) the Sta-
tin Choice and the Aspirin Choice, or 2) the Diabetes
Medication Choice decision aid. Each practice will also
serve as the usual care arm for the other intervention
arm (Figure 2). This approach will seek to ensure similar
representation of ‘easy’ and ‘difficult’ practices in both
decision aid groups and eliminate the need for any site
to simply serve as a usual care arm. A study statistician
will perform the randomization centrally after the prac-
tices have been enrolled, ensuring concealment of
allocation of the paired practices. Practices, clinicians,
patients, and investigators will not be masked to the
intervention. However, patients providing outcomes will
remain masked to their practice status, as consent docu-
ments will keep patients unaware of the study’s main hy-
potheses. Furthermore, we will centrally follow patients
and ensure that patient surveys and pharmacy follow-up
are completed according to the intention-to-treat principle.
Intervention
The intervention will consist of the use of a decision aid
(Statin Choice and Aspirin Choice, or Diabetes Medica-
tion Choice) by patients and their primary care clinician
during the clinical encounter (http://kercards.e-bm.info).
Decision aids
The Statin Choice decision aid has three different ver-
sions according to baseline 10-year cardiovascular risk,
pre-assessed for each patient: 10% (used for patients
with a 10-year cardiovascular risk <15%), 20% (for
patients with estimated risk between 15 and 30%), and
50% (for patients with estimated risk >30%) [6,11]. The
decision aid also presents the absolute risk reduction of
cardiovascular events with statins, the potential downsides
Identification & recruitment 
practices
Intervention Arm 
Randomization 
Clinical encounter 
use of decision aids Video recordings 
Interviews with  
Clinicians, Patients & 
Clinic Support Staff 
Recruitment of
Clinicians & Patients 
Patients & clinicians 
post-encounter survey 
Patients adherence &
decision quality 
3&6 months 
Usual care Arm (Control) 
Clinical encounter 
usual care 
Recruitment of
Clinicians & Patients 
Patients & clinicians 
post-encounter survey 
Patients adherence &
decision quality 
3&6 months 
Video recordings 
Interviews with  
Clinicians, Patients & 
Clinic Support Staff 
Figure 1 Study design.
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of taking statins, and a question prompting patients to ex-
press whether they are ready or not to make a decision
and consequently which action they would like to take.
The Aspirin Choice decision aid is similar to the Statin
Choice decision aid with the only difference being that it
presents the absolute risk reduction of cardiovascular
events with aspirin. The Diabetes Medication Choice deci-
sion aid takes the form of cards that compare commonly
used diabetes medication classes across several domains
(e.g., reduction in HbA1c, weight gain, cost, mode of
administration) that patients with type 2 diabetes and
clinicians consider important when choosing these medi-
cations [7,8].
Training of clinicians
A study team member will conduct a demonstration
showing how to use the decision aid at the time of the
initial in-person discussion with clinics. The focal points
of the demonstration will be that decision aids serve as
guides for conversation rather than scripted discussions;
that clinicians have flexibility in the manner in which
they use the decision aid, including how and when they
use them during the visit; and that they may elect not to
use the tools with certain enrolled patients, per their
own judgment. Brief video clips and storyboards that
demonstrate the basic use of decision aids are publicly
available at http://kercards.e-bm.info for clinicians to re-
view at their convenience. A study team member will re-
main available to do one-on-one demonstrations after
the initial group demonstration if needed.
Usual care
For patients in the usual care arm, clinicians will manage
the discussion about medication regimen as usual, with-
out using decision aids.
Is patient a candidate for starting a diabetes medication? 
T2 diabetes for ≥ 1 year; HbA1c>7.3; not on insulin; On 0, 1, or 2 
medication at maximum doses; no contraindication to diabetes 
medication, per clinician 
Does patient meet general eligibility requirements for 
study participation? 
Signed research authorization; adult (≥ 18 years) with diagnosis of type 2 
diabetes; recognize clinician as main diabetes care provider; available for 
follow-up for six months after treatment decision; no major barriers to 
provide written informed consent 
Is patient a candidate for 
starting either a statin or 
aspirin?
Not taking a statin or aspirin, 
respectively; no contraindication to 
statins or aspirin, per clinician 
Is patient a candidate for starting 
aspirin?
Not taking aspirin; no contraindication to aspirin, 
per clinician 
Is patient a candidate for starting a statin?
Not taking statins; no contraindication to statin, per clinician 
Is patient also a 
candidate for starting 
either a statin or
aspirin?
Not taking a statin or aspirin, 
respectively; no 
contraindication to statins or 
aspirin, per clinician 
Statin
DA
Diabetes
Medication
DA
Is patient a candidate for 
starting a diabetes 
medication? 
T2 diabetes for ≥ 1 yr; HbA1c 
>7.3; not on insulin; on 0, 1, or 2 
medication at max doses; no 
contraindication to diabetes 
medication, per clinician
Control
usual CV 
care 
Not eligible 
for study No
Not eligible 
for study No
Patient is seen at site
using diabetes medication DA 
Patient is seen at site
Using cardiovascular medication DA 
Yes Yes 
Yes No
Not eligible 
for study 
No Yes 
Yes 
Yes No
No Yes 
Not eligible 
for study 
No
Control
usual 
diabetes
care
Yes 
Is patient also a 
candidate for 
starting a diabetes 
medication? 
T2 diabetes for ≥ 1 yr; 
HbA1c>7.3; not on 
insulin; On 0, 1, or 2 
medication at max 
doses; no 
contraindication to 
diabetes medication, 
per clinician 
Aspirin  
DA
Figure 2 Eligibility criteria and assignment by arms.
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Frameworks
The RE-AIM framework will guide this study (aim 1).
This framework has been developed specifically to ad-
dress how an intervention, in this case use of decision
aids, is implemented in a real-world setting [12,13].
Dimensions of the RE-AIM include: Reach (how broadly
is this intervention used within the practices), Effective-
ness (what is the impact of the intervention on out-
comes), Adoption (can this be adopted by new groups
with ease and minimal modifications), Implementation
(what are the special issues and barriers in implementa-
tion), and Maintenance (can the intervention be main-
tained and will the impact continue) [12,13]. To
complement the RE-AIM framework, we will use the
Normalization Process Theory (aim 2) [6,14]. This ap-
plied theoretical model focuses attention on the practical
work that facilitates understanding of the factors that
promote and inhibit the routine embedding of interven-
tions, such as decision aids into practice, in a structured
and parsimonious way. The combination of an estab-
lished implementation framework and robust explana-
tory model will provide a strong foundation for process
evaluation of the trial.
Data collection & analysis
Aim 1. Evaluating the impact of patient decision aids
We will collect patients’ data through 1) self-reported
questionnaires administered before and after the clinical
encounter with their clinician, and at 3 and 6 months
post encounter; and 2) information about diabetes-
related care included in medical records. Participating
clinicians will be given a brief questionnaire to complete
immediately following each clinical encounter with a
participating patient. In addition, we will videotape each
clinical encounter. Practice data will be obtained from
administrative and patient medical records.
Outcomes measures To assess Effectiveness of the deci-
sion aids (RE-AIM) we will measure the decisional con-
flict as the primary outcome and patient involvement in
decision making, diabetes care processes, medication ad-
herence, glycemic and cardiovascular risk factor control,
and resource utilization as secondary outcomes, in the
following way:
 Patients’ decisional conflict. Patients will complete,
immediately after the clinical encounter with their
clinician, a modified version of the Decisional
Conflict Scale [15], the most commonly used
outcome measure in decision aid trials [5]. These
modifications entail the use of brief items that
explore the quality of the deliberation process
during the visit. Psychometric properties include
good internal consistency, test–retest reliability, and
effect sizes for responsiveness to change ranging
from 0.4 to 1.2 [15,16].
 Patients’ involvement in decision making. We will
use the OPTION scale to assess the extent to which
clinicians seek to engage patients in decision making
[17,18]. OPTION is a third-person observer scale
and was designed for use in reviewing audio
recordings of primary care visits. Our group has
extended the use of this tool to video recordings
with excellent inter-rater reliability (intraclass
correlation coefficient >0.7) [6,19,20].
 Patients’ knowledge. Patients will complete a
knowledge questionnaire immediately following the
encounter with their clinicians, and at 3 and 6
months post-encounter. The questionnaire was
developed according to prior recommendations and
is similar to questionnaires used in our previous
studies, addressing general knowledge about diabetes
and lipid management and specific information
contained in the decision aids [6,8].
 Patients’ satisfaction. Satisfaction with decision
making will be assessed using items from the
Decisional Conflict Scale [15] as well as two
specific questions that require patients to assess the
extent to which they would want for themselves
and recommend to others similar decision support
as they received during the visit. Other
questionnaires exist to specifically address this
domain, but our use of the Decisional Conflict
Scale for this purpose reflects our effort to
minimize participant burden.
 Patients’ quality of life. Patients will assess their
health-related quality of life prior to the clinical
encounter through the use of the EuroQol EQ-5D
scale in which they list their health as excellent, very
good, good, fair or poor [21]. The EQ-5D has been
used in primary care [22,23] and in diabetes care
and diabetes trials [24,25].
 Patients’ hemoglobin A1c, lipids, blood pressure, &
body mass index. Medical records will be the source
of information about these commonly used
intermediate outcome measures for diabetes [26,27].
 Patients’ prescription drugs. Prescription drug and
billing data will be collected through pharmacy
records. Patients will be asked to provide written
authorization to contact their pharmacy and release
this information to the investigators. We have been
able to obtain complete pharmacy records for all of
our participants in previous trials [6,8].
 Patients’ adherence. Adherence and persistence
measures will be derived from patient self-report,
metabolic outcomes (indirect measure), and
pharmacy records. These diverse sources are
necessary given the nature of medications (e.g.,
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multiple dosing and dose adjustments, particularly
of insulin, for diabetes medication) [28,29].
 Clinicians’ satisfaction. Clinicians will complete a
brief questionnaire after each encounter where we
will ask about their satisfaction regarding the
discussion they had with their patient about starting
a medication.
 Costs and resource utilization. We will collect cost
and utilization data from patients using two
methods: first, by attempting to collect billing data
from all clinicians the patient reports seeing in the
six-month period and second, by collecting data on
resource utilization from the patient questionnaire
at six months. Data collected will include the
number of hospitalizations, reason for
hospitalization, whether the hospitalization was for
medical or surgical condition, and the length of
hospital stay. Additionally, we will collect data on
emergency room and ambulatory care utilization.
This utilization data will be costed according to the
methods described by Glick et al. [30]. We will
evaluate the economic impact of decision aid
implementation from the clinician perspective based
on the length of visits. The incremental time for
decision aid visits will be considered the opportunity
cost of using a decision aid. We will convert this
incremental time to potential number of additional
diabetes-related visits that could have been
scheduled in 12-months in place of decision aid
assisted visits. The visits will be costed using the
Medicare Fee schedule for a diabetes-related visit.
We will add the costs of materials (decision aids) to
estimate the total practice-related costs.
To assess the Reach of the decision aids (RE-AIM), we
will use a tracking log to record patients who are en-
rolled as well as those who declined the invitation to
participate. We will use this data to evaluate reach, e.g.,
the ratio of enrolled patients to invited patients in each
clinic and the characteristics of eligible patients who en-
rolled and declined. This will allow us to measure par-
ticipation and representativeness.
To assess the Adoption of the decision aids (RE-AIM),
we will estimate the proportion of practices or clinicians
who adopt the intervention. Using clinician surveys and
medical record review, we will compare the adoption
rates across the intervention practices. We will select a
random sample of medical records from each site to de-
termine the extent to which the use of the decision aid
is discernible in the records, and the extent of use and
success when mentioned.
To assess the Implementation of the decision aids (RE-
AIM), we will seek to determine the extent to which the
intervention is implemented as intended. Using the
video recordings of the clinical encounters, we will as-
sess the fidelity with which the decision aids are
delivered and used as intended during these clinical
encounters. We have developed a fidelity checklist for
each of the decision aids. These checklists have 10 to 12
items and are completed by a third observer reviewing
the video recordings of the encounters [20].
To assess the Maintenance of the decision aids (RE-
AIM), we will conduct a site visit and medical record re-
view of eligible patients, approximately six months after
removing investigator implementation support from the
sites. This medical record review is in addition to the
reviews that will take place at three and six months fol-
lowing the study visit.
Socio-demographic characteristics We will ask
patients to report demographic information that is not
available in the medical record, such as marital status,
years of education, occupation, and household income.
We will collect the following characteristics for clini-
cians: type of practice, years in practice and at practice
site, gender, birth year, ethnicity, race, estimate of time
in direct patient care, proportion of practice devoted to
patients with diabetes, and average length of appoint-
ments with diabetes patients. Data will be collected to
characterize participating practices including race, eth-
nicity, and insurance status of patients seen in the prac-
tice; practice type, community size, and make-up of staff
including clinicians, allied health staff, and patient
educators.
Sample size A total of 8 practices will be randomized to
1) the Diabetes Medication Choice decision aid plus sta-
tin and aspirin usual care or 2) the Statin Choice and
Aspirin Choice decision aids plus diabetes medication
usual care. The Statin Choice cluster randomized trial
evaluated decision quality comparing the decision aid to
usual care. This study reported a 9.8 point difference in
decision quality3 with the standard deviation of 16.9 and
14.1 for the usual care and decision aid groups, respect-
ively. Making the following assumptions: 1) variances
are as reported in this study; 2) we seek to detect a dif-
ference of 9.8 points or greater in decision quality be-
tween two groups at significance level of 0.05, with a
two-sided t-test; 3) a modest correlation of outcomes
across these clinicians and practices (which is a conser-
vative assumption) represented by an intracluster correl-
ation coefficient (ICC= between cluster variance/total
variance) of 0.05; 4) a variance inflation or design effect
factor [1+ (n− 1) · ICC], where n is the number of
patients per cluster [31]; and 5) an approximated 20% at-
trition rate, we will have 80% power if we are able to re-
cruit 30 patients per clinic for a total recruitment target
of 240 patients. Assuming a similar ICC and attrition
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rate for other outcomes, this sample size will have 99%
power to detect a 1 SD difference in any continuous
measure (e.g., approximately a 2-point difference in a
10-question knowledge scale), and 80% power to detect
a 30% difference in 6-month adherence rates assuming a
control adherence rate of 50%. Actual power will be
likely greater because we will adjust for baseline values
and characteristics and because of our conservative
assumptions.
Analysis We will have a summary of the cluster level
and patient level characteristics within each trial arm,
providing counts and frequencies for categorical vari-
ables and means with ranges for continuous variables.
Because of the uncertainty as to the ability of a cluster
trial to create uniform prognostic groups, we will test
the null hypothesis of no difference between arms in
baseline cluster level characteristics using the weighted
paired t-test [32]. This test can account for the small
number of clusters and an unequal number of patients
within each cluster.
To account for the modified study design (e.g., each
arm being both intervention and usual care), the study
team assumes similar adherence rates within statin med-
ications and diabetes medications along with similar
knowledge, decisional conflict, and satisfaction rates for
patients discussing either medication for those within
the usual care group. For the decision aids (Statin, As-
pirin and Diabetes Medication) the study team assumes
the same impact on all of these outcomes for all decision
aids. With these assumptions, all patients that use a de-
cision aid during the encounter of interest will be
grouped in the decision aid arm and those that do not
will be grouped under the usual care arm. To account
for differences that may exist between the diabetes, sta-
tin, and aspirin patients, all models will be adjusted by
group. Interaction between arm and group will be tested
for significance, recognizing that the study will be under-
powered to test for this interaction.
To evaluate the efficacy of the intervention, differences
in all patient level outcomes, for both continuous and
dichotomous outcomes (as well as patient characteristics
at baseline) will be estimated using the random effects
meta-analysis method [31]. This approach has been vali-
dated for matched pair cluster-based studies: differences
in means for continuous outcomes and in proportions
for dichotomous outcomes are estimated and then
pooled across strata. A stratum in terms of a matched-
pair study is considered to be each pair, and in this trial
there are 5 strata. For each outcome, we will thus esti-
mate the effect size and its precision (e.g., 95% confi-
dence interval). The outcomes will be assessed at
baseline, 3 and 6 months. We will estimate the intraclass
correlation coefficient for each outcome along with its
95% confidence interval and report these for informa-
tional purposes only since the number of clusters is in-
sufficient to determine with confidence a true intraclass
correlation124. Within patients that had a diabetes medi-
cation discussion, HbA1c will be collected and categor-
ized to <7.3 versus ≥7.3. This outcome will be analyzed
as described above for categorical outcomes. All analysis
and data management will be conducted utilizing SAS
(version 9, Cary, NC) with use of Stata statistical soft-
ware (version 11.0, College Station, Tx) for primary end-
point analysis.
Patients with missing outcome data will not be
included in assessment of that particular outcome. We
will compare the incidence of missing data for each out-
come between study arms, both absolutely and as a
function of follow-up period. We will report rates of
missing data for each outcome by study arm and known
reasons for missing data. In the event that the rate of
missing data is not independent of study arm or is
greater than the assumed 10% loss to follow-up, we will
conduct sensitivity analyses under a range of assump-
tions about the missing values and assess consistency of
results across those scenarios. In the event that patients
are missing baseline characteristics data, which are
otherwise imbalanced between the two study groups, we
will use imputations to estimate models which include
those characteristics.
Aim 2. Identify, describe, and explain factors that promote
or inhibit the routine embedding of decision aids in urban
and nonurban practices
To evaluate how the decision aids are routinized into
primary care practice, we will conduct a qualitative study
with a subset of participants (patients, clinicians, and
clinic support staff ) at the study sites. The qualitative
study will have two major components, which will in-
clude 1) a qualitative analysis of video-recordings of clin-
icians/patients clinical encounters in both intervention
and usual care arms, and 2) in-depth, semi-structured
interviews with participating patients, clinicians, and
clinic support staff, in both intervention and usual care
arms.
In addition to the video recordings of the clinical
encounters, we will conduct semi-structured, in-depth,
interviews with participating patients, clinicians, and
clinic support staff (Figure 1). Patients will be inter-
viewed within a few weeks after their clinical encounter
so as to remember the details of the visit. Clinicians will
be interviewed after all patient recruitment has been
completed so as to reflect on their management of sev-
eral different patients during this study, both in inter-
vention and usual care arms. Clinic support staff (e.g.,
receptionists, nurses, and medical assistants) will be
interviewed based on their involvement with the study.
LeBlanc et al. BMC Health Services Research 2012, 12:130 Page 7 of 9
http://www.biomedcentral.com/1472-6963/12/130
An experienced qualitative researcher will lead these
interviews and audio-record them with participant con-
sent. Interviews will be no longer than one hour and will
be held at the participating site, at a time deemed most
convenient for the participant. When appropriate, clini-
cians will review excerpts of their own video-recordings
of clinical encounters.
Sample size From the video recordings of clinical
encounters from both arms, we will seek to identify a
maximum variation sample of 30 encounters, according
to patient age (<65 or ≥65), whether the patient is ac-
companied during the visit, and whether there is gender
congruence between patient and clinician. We will con-
duct between 20 and 40 interviews for both, participat-
ing patients and clinicians, in the intervention and usual
care arms of the trial. We will conduct between 10 and
20 interviews with clinic support staff, with a purposive
sample that are most likely to be affected by the use of
the decision aid.
Analysis Patient and clinician interviews and video-
recordings of clinical encounters will be fully tran-
scribed, including observational notes of how the deci-
sion aids are used. A qualitative analysis team of at least
6 people will conduct data analysis by using standard
qualitative content analysis techniques [33-35]. Trust-
worthiness of the analysis will be ensured by: 1) asses-
sing transcripts for consistency, 2) group coding, 3)
coding the first round individually, and 4) coding subse-
quent rounds reiteratively. The analysis team will iden-
tify key themes and will code interview and clinical
encounter transcripts in an iterative process. The team
will use qualitative data management software (NVivo
9.0) to facilitate data organization and coding. Each tran-
script will be independently coded by at least two team
members to establish internal validity. Consensus will be
reached through discussion. Codes, which have quota-
tions assigned to them, will be examined by all analysis
team members to ensure consistent code usage. Coded
data will be compiled and analyzed in the form of
memos as a data reduction strategy to build a concep-
tual model that resonates with the constructs of
Normalization Process Theory [6,14]. An observational
guide will be used to analyze the videotaped encounters.
The guide is designed to document initiation of discus-
sion, length of discussion, engagement of patient in dis-
cussion, topics discussed, use of context, and integration
of decision aids into the medication choice discussion.
Discussion
The proposed trial seeks to determine the impact of pa-
tient decision aids vs. usual care on measures of patient
involvement in decision making, diabetes care processes,
medication adherence, glycemic and cardiovascular risk
factor control, and resource utilization in urban and
rural practices in the Midwestern United States. Upon
completion of this trial, we will have new knowledge
about the effectiveness of diabetes decision aids in these
practices and about the processes that promote or in-
hibit the successful implementation and normalization
of medication choice decision aids in rural and urban
primary care practices.
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